CAMZYOS
CAMZYOS (mavacamten) is a first-in-class oral cardiac myosin inhibitor developed by Bristol Myers Squibb that treats hypertrophic cardiomyopathy (HCM) — a genetic condition in which the heart muscle thickens abnormally and obstructs blood flow. The drug reduces the number of myosin-actin cross-bridges that form during each heartbeat, decreasing the force of contraction and relieving the outflow obstruction that causes breathlessness, chest pain, and syncope. CAMZYOS is approved for symptomatic obstructive HCM and is being studied in non-obstructive HCM — a distinct phenotype with twice the patient population and no approved drug therapy — in an ongoing Phase 3 trial.
Upcoming catalysts
Programs
Hypertrophic Cardiomyopathy
Non-obstructive HCM (nHCM) affects roughly twice as many patients as the obstructive form and causes diastolic dysfunction, impaired exercise tolerance, and symptoms including dyspnea and chest pain — but there is no approved drug therapy for nHCM. CAMZYOS is approved for obstructive HCM; this Phase 3 program tests whether reducing myosin activity also improves functional outcomes (KCCQ-23 score and peak VO2) in the non-obstructive phenotype, with enrollment completion in 2026 anchoring a Q2 2027 readout.